Sort
21,281 grants matching “influenza”
Chimeric enzyme for nucleic acid autohydrolysis
$496,886James Williams · Nature Technology Corporation · R44 · FY2006 · GM
Task A04: Mouse Models for Evaluation of Therapeutics against Human Seasonal Influenza and Avian Influenza Strains with Pandemic Potential
$496,800Mikayla Cook · Utah State University · N01 · FY2024 · AI
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung
$496,755Harold A Chapman · University Of California, San Francisco · R01 · FY2019 · HL
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung
$496,755Harold A Chapman · University Of California, San Francisco · R01 · FY2017 · HL
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung
$496,755Harold A Chapman · University Of California, San Francisco · R01 · FY2018 · HL
Administrative Core
$496,688Yoshihiro Kawaoka · University Of Wisconsin-Madison · U19 · FY2013 · AI
Molecular regulation of protective CD8 immunity against influenza infection
$496,645Jie Sun · University Of Virginia · R01 · FY2023 · AI
Novel VLP vaccines for pandemic influenza virus
$496,627Richard W Compans · Emory University · R01 · FY2008 · AI
Project 4: Epigenetic modifiers of regulatory T cell function following viral pneumonia
$496,606Benjamin David Singer · Northwestern University At Chicago · P01 · FY2023 · HL
Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
$496,575Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Systems Biology Approach to Study Influenza Vaccine in Children with Autoimmunity
$496,508Maria Virginia Pascual · Baylor Research Institute · U19 · FY2014 · AI
Chemical probes for imaging and treatment of otitis media
$496,496Matthew S Bogyo · Stanford University · R01 · FY2025 · EB
A three-population three-scale social network model to assess disease dispersion
$496,444Ling Bian · State University Of New York At Buffalo · R01 · FY2018 · GM
Monochromatic 222 nm UV light: Development of a safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission
$496,362Sung-Jin Park · Eden Park Illumination, Inc. · R42 · FY2020 · AI
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung
$496,336Harold A Chapman · University Of California, San Francisco · R01 · FY2016 · HL
Xylitol syrup for the prevention of acute otitis media in otitis-prone children
$496,295Louis Vernacchio · Boston Children'S Hospital · RC1 · FY2010 · DC
Influenza A Inhibits TH17 Host Defense Against Bacterial Pneumonia
$496,186John F Alcorn · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · HL
Metabolic approaches to treat severe viral and inflammatory diseases
$496,085Augusto C Ochoa · Lsu Health Sciences Center · R01 · FY2014 · AI
The geography of H5N1 avian influenza in the United States: Human-environment ecosystem drivers of transmission and viral evolution
$496,076Michael E Emch · University Of North Carolina At Chapel Hill · · FY2025 · SBE
PIGS ARE A MAJOR FOOD ANIMAL SPECIES IN THE US AND GLOBALLY. LOSSES CAUSED BY INFECTIOUS DISEASES [E.G., PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, SWINE INFLUENZA AND PORCINE EPIDEMIC DIARRHEA] DEMONSTRATE THE NEED FOR EFFECTIVE VACCINES, BIOTHERAPEUTICS AND NUTRITIONAL INTERVENTIONS. THE PIG IS ALSO AN IMPORTANT BIOMEDICAL MODEL FOR DEVELOPMENT, OBESITY, CARDIOVASCULAR, TRANSPLANTATION, AND VACCINE RESEARCH. CURRENT RESEARCH EFFORTS REQUIRE A BROAD RANGE OF IMMUNE REAGENTS, BUT THOSE AVAILABLE FOR PIGS ARE LIMITED. OUR GOAL IS TO GENERATE THESE PRIORITY REAGENTS AND PIPELINE THEM FOR MARKETING. THE PROJECT TEAM WILL PRIORITIZE RESEARCH TARGETS BASED ON INTERNATIONAL INPUT FROM RESEARCHERS. NEWLY IDENTIFIED IMMUNE PATHWAYS, UPDATED LISTING OF COMMERCIALLY AVAILABLE REAGENTS, AND OPEN COMMUNICATION WITH PEERS WILL DETERMINE TARGETS AND AVOID DUPLICATION. BASED ON OUR RESEARCH EXPERTISE, AND THE EXPERIENCE GAINED FROM THE PAST SWINE TOOLKIT EFFORTS, THE TEAM HAS IDENTIFIED BEST IMMUNIZATION AND SCREENING STRATEGIES, DEVELOPED PLANS TO COLLABORATE WITH COMMERCIAL PARTNERS FOR PROTEIN EXPRESSION AND MONOCLONAL ANTIBODY (MAB) PRODUCTION, AND UPDATED PROTOCOLS TO EFFICIENTLY EVALUATE SPECIFICITY AND UTILITY OF REAGENTS. OUR SPECIFIC OBJECTIVES ARE: 1) CLONE AND EXPRESS IMPORTANT SWINE IMMUNE MOLECULES; 2) PREPARE PANELS OF MABS REACTIVE WITH THE SWINE IMMUNE TARGETS AND SLA CLASS I TETRAMERS; 3) USE REAGENTS PRODUCED TO DEVELOP NEW ASSAYS FOR SWINE IMMUNE MARKERS; AND 4) PROVIDE THE VETERINARY COMMUNITY WITH NEW COMMERCIAL REAGENTS AND UP-TO-DATE INFORMATION AND TECHNIQUES FOR THEIR RESEARCH EFFORTS. TOOLS AND REAGENTS GENERATED BY THIS PROJECT WILL UNDOUBTEDLY ADVANCE SWINE AND BIOMEDICAL RESEARCH EFFORTS SUBSTANTIALLY.
$496,014Ohio State University, The · · FY2019 · National Institute of Food and Agriculture
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung
$495,915Harold A Chapman · University Of California, San Francisco · R01 · FY2015 · HL
Generating CTL Against Tumor Associated Peptide Antigens
$495,899Linda A Sherman · Scripps Research Institute, The · R01 · FY2006 · CA
WAVE Regulatory Complex in Primary Immunodeficiency Disease and autoimmunity
$495,723Brian M Iritani · University Of Washington · R01 · FY2025 · AI
Engineered Listeria monocytogenes as an AIDS vaccine
$495,681Immune Disease Institute, Inc. · P01 · FY2003 · AI
Fluorous Solution-Phase Synthesis of Peptides and Oligosaccharides
$495,644Nicola L Pohl · Fluorous Technologies, Inc. · R42 · FY2009 · GM